Clonidine HCl Mucoadhesive Buccal Tablet + Placebo Mucoadhesive Buccal Tablet
Phase 2/3Terminated 0 views this week 0 watching💤 Quiet
Interest: 20/100
20
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chemoradiotherapy-Induced Severe Oral Mucositis
Conditions
Chemoradiotherapy-Induced Severe Oral Mucositis
Trial Timeline
Feb 11, 2021 → May 14, 2023
NCT ID
NCT04648020About Clonidine HCl Mucoadhesive Buccal Tablet + Placebo Mucoadhesive Buccal Tablet
Clonidine HCl Mucoadhesive Buccal Tablet + Placebo Mucoadhesive Buccal Tablet is a phase 2/3 stage product being developed by Monopar Therapeutics for Chemoradiotherapy-Induced Severe Oral Mucositis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04648020. Target conditions include Chemoradiotherapy-Induced Severe Oral Mucositis.
Hype Score Breakdown
Clinical
15
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04648020 | Phase 2/3 | Terminated |